摘要 |
<p>The present invention provides a novel compound represented by a general formula (1) as shown below, which has a glucokinase-activating action in the liver and pancreatic ²-cells and which is useful as an agent for preventing and/or treating diseases caused by hyperglycemia, such as diabetes. A spiroindoline compound represented by the general formula (1), or a salt thereof, or a solvate of the compound or the salt:
[wherein ring A represents a nitrogen-containing 5-10 membered heteroaryl group;
R 1 and R 2 , which are the same or different, each represent a hydrogen atom, a halogen atom, a halo C 1-6 alkyl group, a C 6-10 aryl group, a cyano group, a C 1-6 alkyl group optionally having a substituent, a C 2-6 alkenyl group optionally having a substituent, etc.; R 3 represents a hydrogen atom, a C 1-6 alkyl group optionally having a substituent, etc.; and R 4 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group optionally having a substituent, etc.]</p> |
申请人 |
KOWA COMPANY, LTD. |
发明人 |
OGAMINO, TAKAHISA;YAMAZAKI, YUKIYOSHI;TANIKAWA, SHIN;OKUDA, AYUMU;FUKUDA, TOMOAKI;TOKUDA, OKIHISA;MIYAKE, YOSHIHARU;ITOH, SHINSUKE;ISHIWATA, HIROYUKI |